The Role of Real-World Evidence in Regulatory Submissions in China

Introduction

Real-world evidence (RWE) has become an increasingly important component of drug development and regulatory decision-making globally. In China, the National Medical Products Administration (NMPA) has embraced RWE as part of its strategy to accelerate drug access and strengthen post-market safety. With its vast healthcare system and growing electronic health record (EHR) databases, China is uniquely positioned to generate high-quality real-world data (RWD). The NMPA’s 2020 guidance on RWE formally established a framework for using observational studies, registries, and hospital databases in regulatory submissions. For sponsors, RWE provides opportunities to complement clinical trial data, especially in rare diseases, oncology, and post-market commitments. This article examines how RWE is used in Chinese regulatory submissions, the challenges of data quality, and best practices for sponsors.

Background and Regulatory Framework

China’s RWE Policy Evolution

Before 2020, RWE played a limited role in Chinese submissions. Sponsors relied primarily on randomized controlled trial (RCT) data, with regulators hesitant to accept observational evidence. However, global trends and domestic demand for faster access prompted the NMPA to issue formal RWE guidelines in January 2020, aligned with ICH and WHO frameworks.

NMPA’s 2020 RWE Guidance

The guidance outlines acceptable sources of RWD, including EHRs, registries, insurance databases, and Phase IV studies. It specifies methodological requirements, including bias reduction, data validation, and statistical rigor. Sponsors must predefine how RWE supports regulatory objectives, such as expanding indications or fulfilling post-market requirements.

Case Example: Rare Disease Approval with RWE

A rare disease therapy received conditional approval in China in 2021, supported by limited Phase II trial data supplemented with registry-based RWE. The NMPA accepted the submission, requiring ongoing RWE collection as a post-market condition.

Core Clinical Trial Insights

Applications of RWE in Regulatory Submissions

RWE is used in China to:
Support conditional approvals when RCT data are limited
Expand indications based on real-world patient outcomes
Fulfill post-market pharmacovigilance obligations
Provide long-term safety and adherence data
Support NRDL reimbursement negotiations through pharmacoeconomic evidence
These applications demonstrate RWE’s growing role in bridging clinical trials and real-world practice.

Data Sources in China

China’s extensive hospital network provides large EHR databases. National and provincial registries, particularly for oncology and rare diseases, are expanding rapidly. Insurance claims data are also increasingly available, though integration across provinces remains fragmented.

Challenges in Data Quality

Despite progress, challenges include:
Variability in data standards across hospitals
Incomplete or missing records
Limited interoperability across provinces
Bias in observational study designs
Data localization requirements restricting cross-border sharing
Sponsors must implement robust data cleaning, validation, and bias mitigation strategies.

Integration with Clinical Trials

Hybrid designs combining RCT and RWE data are gaining traction in China. For example, single-arm trials may be supplemented with real-world control arms from registries, providing comparative effectiveness evidence. This integration reduces trial size and accelerates approvals.

Multinational Submission Considerations

The NMPA increasingly collaborates with FDA and EMA on RWE use. Sponsors conducting multinational programs must ensure that RWE generated in China meets ICH E6(R2) GCP standards for data integrity and is harmonized with global methodologies.

Best Practices & Preventive Measures

Sponsors should:
Define regulatory objectives for RWE early in development
Partner with hospitals and registries to ensure data quality
Implement standardized data cleaning and validation procedures
Use advanced analytics, including AI, to reduce bias
Engage regulators early to align expectations on RWE use
Leverage CROs with expertise in RWE operations in China
These practices enhance the credibility and acceptance of RWE in submissions.

Scientific & Regulatory Evidence

The NMPA’s 2020 RWE guidance aligns with FDA’s framework for RWE (2018), EMA’s RWE pilot programs, and WHO principles on observational data use. Evidence shows that RWE complements RCTs by providing generalizability, long-term outcomes, and pharmacoeconomic data, which are critical in reimbursement and market access decisions.

Special Considerations

RWE in pediatrics and rare diseases requires extra scrutiny due to small sample sizes. Oncology RWE often relies on surrogate endpoints such as progression-free survival, which must be validated against RCT outcomes. Sponsors must also address PIPL (Personal Information Protection Law) obligations for patient consent and data privacy.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA early in development if RWE will support submissions, particularly for conditional approvals, indication expansions, or NRDL reimbursement dossiers. Early engagement ensures alignment on methodology and data sources, reducing rejection risks.

Case Studies

Case Study 1: Oncology Indication Expansion

A targeted oncology drug used RWE from 20,000 patients across Tier-1 hospitals to expand its indication in 2022. The NMPA accepted the submission, citing the robustness of registry-based evidence alongside RCT data.

Case Study 2: RWE in Pharmacovigilance

A vaccine sponsor integrated RWE from hospital records to monitor long-term safety. The NMPA approved continued market authorization based on the strength of real-world safety evidence, demonstrating the growing reliance on RWE for pharmacovigilance.

FAQs

1. What is real-world evidence (RWE) in China?

RWE refers to evidence derived from real-world data such as EHRs, registries, and insurance claims, used to support regulatory submissions.

2. When does the NMPA accept RWE?

The NMPA accepts RWE in conditional approvals, indication expansions, pharmacovigilance, and reimbursement negotiations, provided data quality is validated.

3. What challenges affect RWE in China?

Challenges include fragmented data systems, variable data quality, incomplete records, and compliance with PIPL data localization requirements.

4. Can RWE replace RCTs in China?

No, RWE complements but does not replace RCTs. It is most often used to support limited trial data or post-market commitments.

5. How is RWE used in multinational submissions?

Chinese RWE must meet ICH and global standards to be accepted in FDA and EMA submissions, requiring harmonized methodologies.

6. What role do CROs play in RWE studies?

CROs provide expertise in data management, analytics, and compliance, supporting sponsors in designing and executing RWE studies in China.

Conclusion & Call-to-Action

Real-world evidence is reshaping regulatory submissions in China, bridging the gap between controlled trial data and real-world clinical practice. With formal NMPA guidance and expanding hospital databases, RWE provides powerful tools for conditional approvals, indication expansions, and reimbursement negotiations. Sponsors should embrace RWE as a strategic component of clinical development, investing in data quality, regulatory engagement, and CRO partnerships to maximize acceptance and accelerate patient access.